CN212593234U - Heart patch - Google Patents

Abstract

A cardiac patch. A cardiac patch is provided, the cardiac patch comprising: (A) an elastic film comprising a biodegradable material; (B) a porous structure comprising a biodegradable material; the elastic membrane is located on the porous structure.

Description

Heart patch

Technical Field

The present application relates to a cardiac patch, and more particularly to a cardiac patch having a two or more layer structure.

Background

Myocardial infarction and heart failure caused by other factors (toxic substances, drugs, alcohol, genetic variation, gene mutation, etc., viral or bacterial infection) have become an important cause of human death in modern countries. According to statistics, death caused by chronic heart failure and myocardial infarction accounts for more than 50% of cardiovascular death, and the morbidity population of myocardial infarction and heart failure tends to be younger. Myocardial infarction and heart failure have attracted a great deal of attention.

When the coronary artery of the heart is blocked; some genetic variation or important gene mutation, or toxic substance, drug, alcohol, virus or bacterial infection, leads to partial myocardial cell death in ventricular muscle, irreversible damage to the myocardium, and then self-reconstruction of the ventricle, leading to thinning of the ventricular wall and fibroblast proliferation to form scar tissue. Therefore, myocardial infarction and other factors cause the function of the myocardium to be gradually reduced along with the development of the disease process, and finally, heart failure can be caused.

There are four main methods for treating myocardial infarction at present: interventional blood vessel stent, heart bypass operation, drug therapy and end-stage heart transplantation. The former two are mainly used for restoring blood supply of cardiac muscle, the third one is mainly used for providing drug support treatment, but the three fundamentally reverse the left ventricular remodeling of the heart, so the process of suction failure after myocardial infarction cannot be fundamentally reversed, and the heart transplantation is difficult to popularize on a large scale due to severe shortage of donors.

Recent research shows that the remodeling process of the ventricle in the myocardial infarction region can be improved, the proliferation of fiber cells and the formation of fiber tissues are inhibited, and the myocardial function is improved by coating the elastic material on the epicardium to perform mechanical enhancement on the ventricle wall. Possible mechanisms include (1) improvement of local mechanical microenvironment of myocardium, inhibition of fibrocyte proliferation, promotion of myocardial regeneration and angiogenesis; (2) increasing the thickness of the wall of the chamber, reducing the pressure of the wall of the chamber, stabilizing the size of the ventricle, reshaping the geometry of the ventricle and preventing the formation of the aneurysm of the chamber wall.

Early studies used mechanical reinforcement by means of biventricular coating, such as Acorn CorCap Heart support devices and Paracor HeartNet Heart support devices. Left ventricular myocardial augmentation devices such as the Myocor Coapsys left ventricular support device and the CardioClasp heart support device were subsequently developed. The implantation procedure of the above devices is complicated, and the devices are bulky, and excessive contact with normal myocardium may have a detrimental effect on normal myocardium.

Cardiac patches have received much attention as a new treatment modality. The main function of the heart-stem-improving support is to provide good mechanical support for the heart-stem region, improve left ventricular remodeling of the heart and prevent the heart failure. In recent years, some researchers have developed a myocardial-reinforcing material that is partially implanted in a myocardial infarction site to directly act on a diseased site. For example, film made of polyurethane urea (PEUU) was fixed to the site of acute Myocardial Infarction in rats using surgical sutures by Fujimoto et al (see: An Elastic, Biodegradable Cardicarpatch indexes, coating, and research Myocardial modification, 2007). Liao et al implanted a commercial double-layered mesh membrane (inner layer of polypropylene and outer layer of polytetrafluoroethylene) With sutures at the site of chronic Myocardial Infarction in rats (see document: implantation of Left vascular additive modification With clinical tablet, 2010). Chi et al immobilized chitosan-hyaluronic acid/silk fibroin composites to myocardial infarction sites with fibrin glue (see literature: Cardiac repair using chitosan-hyaluronic acid/silk fibroin patches in a rat model with myocarpial interaction, 2013).

The heart patches currently under investigation are focused on the design and selection of materials and structures therefor. In the selection of materials, natural materials and synthetic polymer materials are included. The natural materials comprise common collagen, gel and the like, and have good biocompatibility but poor mechanical properties. The synthetic polymer material comprises Polycaprolactone (PCL), glycerol sebacate (PGS) and the like, and has good mechanical properties but relatively poor biocompatibility. How to select good materials for manufacturing the heart patch is very worth researching and researching. In terms of patch structure selection, including single-layer structures, multi-layer structures, mesh structures and the like, the inherent mechanical properties of different structures are greatly different, and how to design a good structure is also very worth researching and researching.

Lin et al ("A viroelastic adjuvant patch for treating myocardial injury", NATURE BIOMEDICAL ENGINEERING, https:// doi. org/10.1038/s 41551-019-. The advantages of the drug delivery system have better mechanical property, and the disadvantages of the drug delivery system are that the drug delivery system is difficult to operate in clinical application, difficult to transplant to the surface of the heart and has no function of drug delivery.

Jackman et al ("Engineered cardiac tissue specimen structures and electrical properties after medical imaging", Biomaterials,2018) disclose a single layer patch. Yang et al ("Elastic 3D-Printed Polymeric Scaffold Improves cardiovascular remodelling", ADVANCED HEALTHCARE MATERIALS,2019.8) and Lei et al ("3D printing OF biological vascular for tissue regeneration", ROYAL SOCIETY OF CHEMISTRY COMMUNICATION,2019.02) disclose multilayer mesh and multilayer hollow tube structures that have good angiogenic effect but suffer from poor mechanical properties.

Whyte et al ("suspended release of targeted cardiac therapy with a purified implantable systemic respiratory response", NATURE BIOMEDICAL ENGINEERING, https:// doi. org/10.1038/s 41551-018. sup. 0247-5) disclose a cardiac patch for cardiac surface drug delivery, which has the greatest disadvantage of poor mechanical strength of the patch material, no good elasticity, no degradability, and no good mechanical support for the heart.

Therefore, there is a great need in the art for a cardiac patch having the following properties: good mechanical strength and elasticity, degradability and biocompatibility and versatility (such as drug delivery).

SUMMERY OF THE UTILITY MODEL

In order to achieve the above object, the present application provides a cardiac patch comprising:

(A) an elastic film comprising a biodegradable material;

(B) a porous structure comprising a biodegradable material;

the elastic membrane is located on the porous structure.

In a preferred example of the present application, the biodegradable polymer material includes polypeptides, polyamino acids, polyurethanes, polyesters, polylactic acids, chitin, collagen/gelatin, polycaprolactone, polysebacic acid glyceride, and combinations thereof.

In a preferred example of the present application, the material used to form the elastomeric film includes polycaprolactone, polysebacic acid glyceride and combinations thereof.

In a preferred embodiment of the present application, the material used to form the elastomeric film comprises a mixture of polycaprolactone and polysebacic acid glyceride; alternatively, the material for forming the elastic membrane comprises a mixture of materials in a weight ratio of 5: 95-95: 5, preferably in a weight ratio of 10: 90-90: 10, more preferably in a weight ratio of 20: 80-80: 20, and preferably in a weight ratio of 30: 70-70: 30.

in a preferred embodiment of the present application, the elastic membrane typically has a compressive modulus of 1 to 20 MPa; the tensile modulus of the elastic film is usually 0.1 to 10 MPa.

In a preferred example of the present application, the porous structure comprises a plurality of biomimetic blood vessel layers, wherein the biomimetic blood vessel orientations of the biomimetic blood vessel layers of two adjacent layers are the same or different.

In a preferred example of the application, the orientations of the bionic blood vessels of the adjacent two bionic blood vessel layers are different; preferably, the bionic blood vessels of the adjacent two bionic blood vessel layers are oriented at 5-90 degrees; more preferably, the bionic blood vessels of the adjacent two layers of the bionic blood vessel layers are orthogonally placed.

In a preferred embodiment of the present application, the porous structure comprises 2-10, preferably 2-8, more preferably 2-6, and most preferably 2-4 layers of biomimetic blood vessel layers.

In a preferred embodiment of the present application, the cardiac patch further comprises a catheter.

Drawings

Fig. 1 depicts a schematic view of a cardiac patch as described herein.

Fig. 2 is a photograph of four composite porous structures of example 1 at different ratios, wherein a is a pure PCL scaffold, b is PCL: gelatin 3:1, c is PCL: gelatin 1:1 and d is a pure gelatin stent.

Fig. 3 is a photograph of thin films of elastic composite films of PCL and PGS in different proportions, where a is a PGS film, b is a PGS/PCL-9: 1 composite film, c is a PGS/PCL-8: 2 composite film, d is a PGS/PCL-7: 3 composite film, and e is a PCL film.

Figure 4 is a micrograph of a pure PCL scaffold.

FIG. 5 is a photomicrograph of a PCL/gelatin (3:1) scaffold.

FIG. 6 is a photomicrograph of a PCL/gelatin (1:1) scaffold.

Fig. 7 is a photomicrograph of a pure gelatin stent.

FIG. 8 is a sectional electron micrograph of the thin film, wherein a-b are 75-fold and 800-fold electron micrographs of pure PGS film, c-d are 75-fold and 800-fold electron micrographs of PGS/PCL 9:1 film, and e-f are 75-fold and 800-fold electron micrographs of pure PCL film, respectively.

FIG. 9 is an electron micrograph of the surface of a thin film, wherein a-b are 75-fold and 800-fold electron micrographs of a pure PGS film, c-d are 75-fold and 800-fold electron micrographs of a PGS/PCL 9:1 film, and e-f are 75-fold and 800-fold electron micrographs of a pure PCL film, respectively.

Fig. 10 depicts the contact angles of scaffolds of different materials.

Fig. 11 depicts contact angles for films of different materials.

Fig. 12 depicts the mechanical properties of a porous structure, where a is the single compression plot and b is the cyclic compression plot.

FIG. 13 shows a histogram of the compressive modulus of the stent versus the compressive modulus of the stent.

Fig. 14 depicts the mechanical properties of an elastic film, where a is the tensile break plot, b is the cyclic tensile plot, c is the single compression plot, and d is the cyclic compression plot.

FIG. 15 shows a histogram of film modulus versus tensile modulus where a is the compressive modulus versus b.

FIG. 16 depicts the photographs obtained for PET.

Detailed Description

In this context, percentages (%) or parts are percentages by weight or parts by weight relative to the composition, unless otherwise specified.

In this context, the individual components mentioned or their preferred components can be combined with one another to form new technical solutions, if not stated otherwise.

All embodiments and preferred embodiments mentioned herein can be combined with each other to form new solutions, if not specified otherwise.

In this context, all technical features mentioned herein, as well as preferred features, can be combined with each other to form new technical solutions, if not specifically stated.

In this context, the sum of the contents of the individual components in the composition is 100%, if not stated to the contrary.

In this context, the sum of the parts of the components in the composition may be 100 parts by weight, if not stated to the contrary.

In this context, unless otherwise stated, the numerical range "a-b" represents a shorthand representation of any combination of real numbers between a and b, where a and b are both real numbers. For example, a numerical range of "0 to 5" indicates that all real numbers between "0 to 5" have been listed herein, and "0 to 5" is only a shorthand representation of the combination of these numbers.

As used herein, unless otherwise indicated, the range of integer values "a-b" represents a shorthand representation of any combination of integers between a and b, where a and b are both integers. For example, an integer numerical range of "1-N" means 1, 2 … … N, where N is an integer.

In this context, unless otherwise stated, "combinations thereof" means multi-component mixtures of the individual elements mentioned, for example two, three, four and up to the maximum possible multi-component mixtures.

The term "a" or "an" as used herein means "at least one" if not otherwise specified.

Percentages (including weight percentages) recited herein are based on the total weight of the composition, unless otherwise specified.

The "ranges" disclosed herein are in the form of lower and upper limits. There may be one or more lower limits, and one or more upper limits, respectively. The given range is defined by the selection of a lower limit and an upper limit. The selected lower and upper limits define the boundaries of the particular range. All ranges that can be defined in this manner are inclusive and combinable, i.e., any lower limit can be combined with any upper limit to form a range. For example, ranges of 60-120 and 80-110 are listed for particular parameters, with the understanding that ranges of 60-110 and 80-120 are also contemplated. Furthermore, if the minimum range values 1 and 2 are listed, and if the maximum range values 3, 4, and 5 are listed, the following ranges are all contemplated: 1-3, 1-4, 1-5, 2-3, 2-4, and 2-5.

Herein, unless otherwise specified, each step is performed at normal temperature and pressure.

Herein, unless otherwise specified, the individual reaction steps may or may not be performed sequentially. For example, other steps may be included between the various steps, and the order may be reversed between the steps. Preferably, the reaction processes herein are carried out sequentially.

Herein, unless otherwise indicated, the devices or components thereof may be conventional in the art and operate and/or connect in a manner conventional in the art. For example, the various components of the device may be connected by conduits, lines, or combinations thereof for mass transfer or energy transfer.

The present application provides a cardiac patch comprising:

(A) an elastic film comprising a biodegradable material;

(B) a porous structure comprising a biodegradable material;

the elastic membrane is located on the porous structure.

Elastic film

The material used to form the elastic membrane is a biodegradable material, which may include biodegradable polymeric materials and biodegradable ceramic materials. The biodegradable polymer material includes, but is not limited to, polypeptides, polyamino acids, polyurethanes, polyesters, polylactic acids, chitin, collagen/gelatin, polycaprolactone, polysebacic acid glyceride, and combinations thereof. The biodegradable ceramic material includes, but is not limited to, P-tricalcium phosphate. In one example of the present application, materials for forming the base film include, but are not limited to, polyurethane, polyester, polylactic acid, chitin, polycaprolactone, polysebacic acid glyceride, and combinations thereof. In another example of the present application, materials for forming the elastic film include, but are not limited to, polycaprolactone, polysebacic acid glyceride, and combinations thereof. In another example of the present application, the material for forming the base film includes a mixture of polycaprolactone and polysebacic acid glyceride. In a preferred example of the present application, the material for forming the base film includes a material having a weight ratio of 5: 95-95: 5, preferably in a weight ratio of 10: 90-90: 10, more preferably in a weight ratio of 20: 80-80: 20, and preferably in a weight ratio of 30: 70-70: 30.

methods for forming elastic films are known in the art, such as casting, extrusion, casting, calendering, and the like. The method of forming the base film may cause the biodegradable material to crosslink. For example, in the case of using a mixture of polycaprolactone and polysebacic acid glyceride, the polycaprolactone and polysebacic acid glyceride crosslink during the formation of the elastic film. In one embodiment of the present application, the polycaprolactone and polysebacic acid glyceride are crosslinked under vacuum at a temperature of 100 ℃ and 250 ℃ for 10-72 hours.

Generally, the thickness of the elastic film is generally 0.1 to 5mm, preferably 0.2 to 3mm, more preferably 0.3 to 2mm, and most preferably 0.5 to 2 mm. The thickness of the base film can be adjusted according to actual needs.

Generally, the elastic film has good elasticity and large-scale deformation recovery, while having good fatigue resistance. The elastic film typically has a compressive modulus of from 1 to 20MPa, preferably from 2 to 15MPa, more preferably from 3 to 10MPa, most preferably from 4 to 8 MPa; the tensile modulus of the elastic film is generally 0.1 to 10MPa, preferably 0.5 to 5MPa, more preferably 0.8 to 4MPa, and most preferably 1 to 3 MPa.

Porous structure

The material for forming the porous structure is the same as or different from the material for forming the base film. The material used to form the porous structure is a biodegradable material, which may include a biodegradable polymeric material. The biodegradable polymer material includes, but is not limited to, polypeptides, polyamino acids, polyurethanes, polyesters, polylactic acids, chitin, collagen/gelatin, polycaprolactone, polysebacic acid glyceride, and combinations thereof. In one example of the present application, the material used to form the porous structure includes collagen/gelatin, polycaprolactone, polysebacate, and combinations thereof.

The specific structure of the porous structure is well known in the art, and may be, but is not limited to, a multi-layered mesh structure or a multi-layered hollow tube structure. The multilayered network can be found in Yang et al ("Elastic 3D-Printed Hybrid Polymeric samples improvement after polyester fibrous Infation", ADVANCED HEALTHCARE MATERIALS, 2019.8). The multilayer hollow tube structure can be found in Lei et al ("3D printing OF biological design for tissue regeneration", ROYAL SOCIETY OF CHEMISTRY COMMUNICATION, 2019.02).

In a preferred example of the present application, the porous structure comprises a plurality of biomimetic blood vessel layers, wherein the biomimetic blood vessel orientations of the biomimetic blood vessel layers of two adjacent layers are the same or different. Preferably, the orientations of the bionic blood vessels of the two adjacent bionic blood vessel layers are different, for example, the orientations of the bionic blood vessels of the two adjacent bionic blood vessel layers are 5-90 degrees, more preferably 15-90 degrees, still more preferably 30-90 degrees, still more preferably 45-90 degrees, and most preferably 60-90 degrees. In one example of the present application, the biomimetic blood vessels of the two adjacent layers of biomimetic blood vessels are orthogonally placed.

In one embodiment of the present application, the diameter of the biomimetic blood vessel is about 0.01-1mm, more preferably 0.02-0.5mm, still more preferably 0.05-0.2 mm.

In one example of the present application, the porous structure has 2 to 10 layers of the biomimetic blood vessel layer, preferably 2 to 8 layers of the biomimetic blood vessel layer, more preferably 2 to 6 layers of the biomimetic blood vessel layer, and most preferably 2 to 4 layers of the biomimetic blood vessel layer.

The thickness of the porous structure is generally 0.1 to 5mm, preferably 0.2 to 3mm, more preferably 0.3 to 2mm, and most preferably 0.5 to 2 mm. The thickness of the porous structure body can be adjusted according to actual needs.

Methods for forming porous structures are well known in the art. For example, see Yang et al ("Elastic 3D-Printed Hybrid Polymeric Scaffold improvings rearward modifying after Myocardial Infation", ADVANCED HEALTHCARE MATERIALS,2019.8) and Lei et al ("3D printing OF biological design for tissue regeneration", ROYAL SOCIETY OF CHEMISTRY COMMUNICATION, 2019.02).

Typically, the tensile modulus of the porous structure is 120-750kPa, preferably 150-600kPa, more preferably 200-500 kPa; a tensile break strength of 20 to 300kPa, preferably 50 to 250kPa, more preferably 100 kPa to 200 kPa; the tensile elongation at break is more than 35%, preferably more than 50%, more preferably more than 100%, still more preferably from 35% to 300%.

The porous structure body can also be used for loading drugs for treating myocardial infarction, and also can be macromolecular proteins such as polypeptide, growth factors and the like, genes, stem cells and the like. Such drugs include, but are not limited to, neomycin, digoxin, codantone, levosimendan, lidocaine, epinephrine, and combinations thereof. The porous structure may be immersed in a drug solution to load the drug in the pores of the porous structure.

Methods of bonding the porous structure and the substrate film together include, but are not limited to, pressing the porous structure and the substrate film together, adhering the porous structure and the substrate film together with an adhesive, or placing the substrate film on the porous structure and heating.

The heart patch may further include a conduit for releasing the drug loaded in the porous structure to the heart. The conduit may pass through the basement membrane with one end contacting the porous structure and the other end contacting the cardiac tissue.

Catheter tube

The cardiac patch described herein may also include a catheter. Typically, the catheter contacts the porous structure through the elastic membrane from the middle (e.g., central) of the elastic membrane to facilitate the sustained delivery of the drug in the porous structure to the heart.

One end of the conduit may also include a sheet adaptor to facilitate attachment of the conduit to the porous structure.

The material used to form the conduit and sheet adaptor may be a biodegradable material, which may be the same or different from the material forming the porous structure or elastic membrane.

In another aspect, the present application also provides the use of a mixture of polycaprolactone and polysebacic acid glyceride for the preparation of a heart patch. In particular, the cardiac patch may be used to treat cardiac diseases including, but not limited to, myocardial infarction and the like. In a preferred embodiment of the present application, the use comprises improving a mechanical property of the heart patch, such as tensile modulus or compressive modulus.

Fig. 1 depicts a schematic view of a cardiac patch as described herein. The heart patch comprises an elastic membrane 1 and a porous structure 2.

The present application is further illustrated by the following examples, but the scope of the present application is not limited thereto.

Example 1: 3D printing construction of three-dimensional structure bionic vascular network Stent (PHMs)

The template of the bracket is printed by Fused Deposition Modeling (FDM), and sucrose is selected as a raw material of the template. The model required for 3D printing was selected using the shanghai fuqifan extrusion 3D printer (HTS-400) (the conventional Box model was chosen for this experiment). The squeeze bar is then lowered to compact the white sugar in the barrel to prevent it from being oxidized by air. And (3) turning on a heating device of the No. 2 head, setting the temperature of the extrusion cavity and the temperature of the nozzle to be 160 ℃, and preheating. And then parameter setting is carried out: the layer height was 0.45mm, the grid fill width was 1.2mm, the x position was 160, the y position was 120, the number of contour fills was 0, and the angles were 90 ° and 0 °. And clicking the XY axis speed in the menu, filling the corresponding XY axis movement speed and T axis extrusion speed, wherein the XY axis movement speed is 2.4-2.6mm/s, the T axis extrusion speed is 0.007-0.008mm/s (adjusted according to subsequent printing conditions), saving data, clicking 'confirm' and filling the path. Then the x-axis position is adjusted to 160, the y-axis position is adjusted to 120, and the height of the needle head away from the receiving plate is adjusted by adjusting the z-axis, so that the sucrose can be attached to the receiving plate after being extruded. Finally clicking the 'return-to-zero' to return the printer to the initial position, and setting the extrusion cavity temperature and the nozzle temperature to 130- & ltSUB & gt-135 ℃ (the temperature is changed according to the extrusion flow state of the sucrose, the change of the sucrose fluidity is very sensitive in the temperature range, the temperature is slightly reduced when the extrusion is too fast, and the temperature is slightly increased when the extrusion is too slow), and printing can be started according to Auto.

Polycaprolactone (PCL) and gelatin solutions were formulated in hexafluoroisopropanol in the proportions shown in table 1 below, with a total concentration of 4% and a volume of 10 mL.

Table 1: mixing ratio of gelatin and PCL

Slowly pouring the solution into a container with a sugar mold, completely soaking, clamping the sugar mold with forceps after the outer layer of the sugar mold is fully coated with the solution, placing the sugar mold in a ventilated place to volatilize the solvent (the surface of the template can be properly blown by nitrogen), then placing the template into a 10% glutaraldehyde-ethanol solution to be cured for 2-5min (the pure PCL stent does not need to be cured), finally dissolving the template by water, and freeze-drying to obtain the stent.

Example 2: preparation of elastic films

Three groups of mixed solutions with different proportions are designed, tetrahydrofuran is selected as a solvent, and the mixing ratio is shown in table 2.

Table 2: mixing ratio of PGS and PCL

And pouring the five groups of solutions into a polytetrafluoroethylene mold respectively. Then placing the mixture in a vacuum oven at 150 ℃ and the vacuum degree of-0.1 MPa to crosslink the mixture. And taking out at intervals to check whether the surface is smooth and has or not bubbles. The reaction is more violent in the first two hours, the solvent is possibly volatilized too fast, more bubbles are generated, attention is needed to a vacuum oven at any moment, and the bubbles and holes are prevented from being generated by adjusting the temperature and the vacuum degree. When the reaction becomes slow, the surface is smooth and has no bubbles, the temperature of the oven is kept at 150 ℃, and the vacuum reaction is carried out for about 24 hours.

Example 3: characterization and testing

3.1 macrostructure evaluation

Selecting the bracket compounded by PCL and gelatin in different proportions in the embodiment 1, and evaluating the macrostructure by judging whether the integral structural form of the bracket is complete or not.

Selecting the films compounded by PCL and PGS in different proportions in the embodiment 2, and evaluating the macrostructure by judging whether the overall shape of the film is complete.

Fig. 2 is a photograph of four composite porous structures of example 1 in different proportions, wherein a is a pure PCL scaffold, b is PCL: gelatin 3:1, c is PCL: gelatin 1:1 and d is a pure gelatin stent.

As can be seen in fig. 2, with the addition of gelatin, the structural integrity of the scaffold gradually decreases and the shape retention gradually deteriorates. In fig. 2 d is a pure gelatin stent which does not retain its shape well after removal of the cast and cannot be removed from the water.

Fig. 3 is a photograph of thin films of elastic composite films of PCL and PGS in different proportions, where a is a PGS film, b is a PGS/PCL-9: 1 composite film, c is a PGS/PCL-8: 2 composite film, d is a PGS/PCL-7: 3 composite film, and e is a PCL film.

As can be seen from FIG. 3, the transparency of the pure PGS film is high, the pure PCL film is white and opaque, and the transparency of the PGS/PCL composite film is between the two. Wherein PGS/PCL is 9: the shape of the composite film 1 is better and more uniform, and the ratio of PGS/PCL is 8:2 and PGS/PCL 7:3, and the more PCL is added, the more serious the phase separation is.

3.2 microstructure evaluation

The scaffolds and the film structures obtained in examples 1 and 2 were characterized by scanning electron microscopy, and the morphology of the scaffolds, whether the PHMs channels were maintained, and the microporous structure present inside were observed, and the surface morphology of the films was observed, with no defects or pores.

Figure 4 is a micrograph of a pure PCL scaffold. FIG. 5 is a photomicrograph of a PCL/gelatin (3:1) scaffold. FIG. 6 is a photomicrograph of a PCL/gelatin (1:1) scaffold. Fig. 7 is a photomicrograph of a pure gelatin stent.

As can be seen from the electron microscopy pictures of fig. 4-7, pure PCL scaffolds and 3: the bracket 1 has a relatively complete and clear pipeline structure, and a microporous structure is arranged in the bracket. 1 of fig. 6: the structure of the bracket pipeline is approximately complete, however, the fiber units in the bracket have non-communicated holes, and the inner micropores are less. The pure gelatin bracket pipeline structure of figure 7 has collapse phenomenon, the number of the holes which are not communicated among the fiber units is large, and the internal micropore structure can hardly be seen. In contrast, pure PCL scaffold and 3: the stent 1 has good shape, is provided with a communicated internal pipeline network and a permeable tube wall with a microporous structure, and is more favorable for being used as a tissue engineering stent.

FIG. 8 is a sectional electron micrograph of the thin film, wherein a-b are 75-fold and 800-fold electron micrographs of pure PGS film, c-d are 75-fold and 800-fold electron micrographs of PGS/PCL 9:1 film, and e-f are 75-fold and 800-fold electron micrographs of pure PCL film, respectively.

FIG. 9 is an electron micrograph of the surface of a thin film, wherein a-b are 75-fold and 800-fold electron micrographs of a pure PGS film, c-d are 75-fold and 800-fold electron micrographs of a PGS/PCL 9:1 film, and e-f are 75-fold and 800-fold electron micrographs of a pure PCL film, respectively.

As can be seen from FIG. 8, the three groups of films have smooth sections and good morphology. As can be seen from fig. 9, holes exist on the surface of the pure PCL film; pure PGS film and PGS/PCL ═ 9: the film 1 has smooth surface and no obvious holes or defects.

3.3 contact Angle test

The test was performed with a fully automatic video microcosmic contact angle gauge (OCA40 Micro). The support and the film with better structural morphology obtained in the embodiments 1 and 2 are selected for testing, distilled water is dripped on the surface of a sample, the volume of the dripped liquid drop is set to be 5 muL, the speed is set to be 1 muL/s, then the outline image of the liquid drop is obtained through a microscope and a camera, and then the contact angle of the liquid drop in the image is calculated by using the analysis processing carried by software. Each set of samples was taken 5-6 valid data and 1-2 videos were taken. Since the ratio of 3:1, support, 1: the hydrophilicity of the bracket 1 and the pure gelatin bracket is good, and the contact angle cannot be read by photographing in time, so that the 3 groups of samples only take videos, and the contact angle is measured by subsequently taking pictures through the videos.

As can be seen from fig. 10, the addition of gelatin significantly increased the hydrophilicity of the scaffold. The initial contact angle of the pure PCL bracket is 101.2 +/-7.9 degrees, the whole bracket is hydrophobic, the contact angle is gradually reduced with the time, the contact angle is reduced to 75.4 +/-2.9 degrees after 25 seconds, and water drops on the sample can still be seen by naked eyes. 3:1, the initial contact angle of the stent is 64.3 +/-3.9 degrees, the whole stent is hydrophilic, the contact angle is reduced to 0 after 3s, and the hydrophilicity is better. 1:1 initial contact angle of the scaffold 51.6 ± 3.1 °, below 3:1 scaffold, and droplet disappearance time less than 3:1, the scaffold has good hydrophilicity. The initial contact angle of the pure gelatin bracket is 47.4 +/-2.2 degrees, the contact angle is the lowest of four groups, and the contact angle is reduced to 0 fastest.

As can be seen from fig. 11, with the addition of PGS, the contact angle of the upper film gradually decreases and the hydrophilicity of the film gradually increases. The contact angle of the pure PCL film is 95.1 +/-5.23 degrees; PGS/PCL 9:1 the contact angle of the composite film is 45.8 +/-4.84 degrees; the contact angle of the pure PGS film was 40.2. + -. 2.67 ℃.

3.4 mechanical Property test

The samples obtained in the examples 1 and 2 are made into small wafers with the diameter of 8mm by a puncher, 3-4 wafers are overlapped, the average diameter and the thickness are read by a vernier caliper and a thickness gauge, single compression, cyclic compression, tensile fracture and cyclic tension experiments are carried out by a universal mechanical testing machine, and a stress-strain curve, a cyclic tension curve and a compression curve are drawn, so that the strength and the modulus of the bracket and the film are obtained. Wherein the deformation degree of the cyclic compression test is 40%, the deformation degree of the compression return stroke is 5%, and the cycle time is 10 times.

Fig. 12 depicts the mechanical properties of a porous structure, where a is the single compression plot and b is the cyclic compression plot. FIG. 13 shows a histogram of the compressive modulus of the stent versus the compressive modulus of the stent.

From a in figure 12 and figure 13, it can be seen that the addition of gelatin increases the modulus, the pure PCL porous structure has the smallest modulus of 5.37 ± 0.89 kPa; 1:1 the modulus of the porous structure is the maximum and is 19.25 +/-2.24 kPa; 3:1 the modulus of the porous structure is between the first two and is 12.75 +/-1.73 kPa. The cyclic compression curve b in fig. 12 shows that the PCL-only stent has good elasticity, the curves of multiple deformation recoveries are basically overlapped, and the fatigue resistance is strong; and as the addition amount of the gelatin is increased, the hysteresis phenomenon is obviously increased, the elasticity of the bracket is reduced, and the fatigue resistance is poorer.

Fig. 14 depicts the mechanical properties of an elastic film, where a is the tensile break plot, b is the cyclic tensile plot, c is the single compression plot, and d is the cyclic compression plot. FIG. 15 shows a histogram of film modulus versus tensile modulus where a is the compressive modulus versus b.

According to fig. 14 and 15, the PGS film compressive modulus is 4.74 ± 0.44MPa, PGS/PCL ═ 9:1 the compression modulus of the composite membrane is 5.87 +/-0.32 MPa; the tensile modulus of the PGS film is 1.03 +/-0.02 MPa, and the ratio of PGS/PCL is 9:1 the tensile modulus of the composite film is 1.61 +/-0.26 MPa. As can be seen from a comparison of fig. 14 and 15, PGS/PCL is 9: the composite film 1 has more excellent mechanical property, and both the strength and the elastic modulus are higher than those of a pure PGS film.

Example 4: heart patch animal experiment test result

Animal species and source: the healthy male Sprague-Dawley rat has the body mass of 200-: SYXK (Shanghai) 2013-.

Animal model: myocardial infarction Model (MI)

The specific model construction method comprises the following steps: after the SD rat is subjected to gas anesthesia, the SD rat is fixed on an operating table, a small animal respirator (DW-3000A/B, Beijing Zhongdi Chuang Limited responsibility for technology development) maintains the respiration of the SD rat, the chest is unhaired and disinfected to spread a towel, the thoracic cavity is opened in the 4 th to 5 th intercostal gaps on the left side, the pericardium is opened, the heart of the SD rat is exposed, a 6-0 Proleline (prolene) suture line is sutured at the position of about 3-4 mm of the front lower part of the left auricle, the anterior descending branch of the left coronary artery is ligated, the pale heart apex and anterior wall myocardial tissues can be observed after ligation, and the contraction motion of the.

Grouping experiments:

the sham operation group: negative control, consistent with model construction except that the left anterior descending coronary artery was not ligated, n-5

MI group: myocardial infarction Model (MI), n ═ 5

PCL group: MI + PCL, n ═ 5

PGS group: MI + PGS, n ═ 5

PGS/PCL 9:1 group: MI + PGS/PCL, n ═ 5

The PCL group is a short for a double-layer patch device, the elastic membrane is made of PCL, and the multi-hollow structure body is made of PCL/gelatin 3: 1;

the PGS group is a short for a double-layer patch device, the elastic membrane is made of PGS, and the multi-hollow-knot structural body is made of PCL/gelatin 3: 1;

the PGS/PCL 9:1 group is a double-layer patch device for short, the elastic membrane is made of PCL/PGS 9:1, and the multiple hollow structure body is made of PCL/gelatin 3:1

The patch device transplanting method comprises the following steps:

the patch device was sutured to the surface of the myocardial infarcted heart by 4-needle suturing with 8-0 prolene sutures at 12 o 'clock, 6 o' clock, 9 o 'clock and 3 o' clock, respectively.

The imaging of mouse hearts was performed using Positron Emission Tomography (Positron Emission Computed Tomography, PET, Trans-PET BioCaliburn 700system by Richining technologies, Inc.). FIG. 16 depicts the photographs obtained for PET. In FIG. 16, from left to right are the sham, MI, PCL, PGS and PGS/PCL (9:1) groups, respectively. The results showed that the MI group, PCL group, PGS group and PGS/PCL (9:1) group all exhibited partial metabolic defects in the sham-operated group. In contrast, the PGS/PCL (9:1) group had fewer defects, indicating that the range of stem shuffling was smaller and the therapeutic effect was the best.

TABLE 3 quantitative analysis of PET results

	Artificial operation group	MI group	PCL group	PGS group	PGS/PCL (9:1) group
						n
	5	5	5	5	5
						SUV	8.44±1.19	3.03±0.65	4.52±0.55	4.76±0.49	6.61±1.82

Note: an SUV index Standard Uptake Value (SUV), wherein the larger the value is, the better the metabolism of cardiac myocytes is;

n: number of SD rats per group.

Claims (11)

1. A cardiac patch, characterized in that it comprises:

an elastic film comprising a biodegradable material;

a porous structure comprising a biodegradable material;

the elastic membrane is located on the porous structure.

2. The heart patch of claim 1, wherein the elastic membrane has a compressive modulus of 1 to 20 MPa; the elastic film has a tensile modulus of 0.1 to 10 MPa.

3. The cardiac patch according to claim 1, wherein the porous structure comprises a plurality of biomimetic blood vessel layers, wherein the biomimetic blood vessel orientation of the biomimetic blood vessel layers of two adjacent layers is the same or different.

4. The cardiac patch of claim 3, wherein the biomimetic blood vessel orientation of two adjacent layers of the biomimetic blood vessel layer is different.

5. The cardiac patch according to claim 4, wherein the biomimetic blood vessels of the two adjacent layers are oriented at 5-90 degrees.

6. The cardiac patch of claim 4, wherein the biomimetic blood vessels of two adjacent layers of biomimetic blood vessels are orthogonally positioned.

7. The cardiac patch of claim 3, wherein the porous structure comprises 2-10 biomimetic vascular layers.

8. The cardiac patch of claim 3, wherein the porous structure comprises 2-8 biomimetic vascular layers.

9. The cardiac patch of claim 3, wherein the porous structure comprises 2-6 biomimetic vascular layers.

10. The cardiac patch of claim 3, wherein the porous structure comprises 2-4 biomimetic vascular layers.

11. The cardiac patch of claim 1, wherein the cardiac patch further comprises a catheter.

Images